Jianhong Chu
Overview
Explore the profile of Jianhong Chu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
908
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li Z, Liu X, Wang L, Zhao H, Wang S, Yu G, et al.
Front Immunol
. 2023 Nov;
14:1281687.
PMID: 38022588
Introduction: Acute myeloid leukemia (AML) is a type of blood cancer that is identified by the unrestricted growth of immature myeloid cells within the bone marrow. Despite therapeutic advances, AML...
2.
Xu F, Jiang D, Xu J, Dai H, Fan Q, Fei Z, et al.
Cell Rep
. 2023 Sep;
42(10):113138.
PMID: 37738123
Advances in the development of therapeutic extracellular vesicles (EVs) for cancer immunotherapy have allowed them to emerge as an alternative to cell therapy. In this proof-of-concept work, we develop bispecific...
3.
Jiang D, Huang H, Qin H, Tang K, Shi X, Zhu T, et al.
Nat Commun
. 2023 Jun;
14(1):3642.
PMID: 37339964
BCMA-targeting chimeric antigen receptor (CAR) T cell therapy demonstrates impressive clinical response in multiple myeloma (MM). However, some patients with BCMA-deficient tumours cannot benefit from this therapy, and others can...
4.
Wang W, Zheng H, Jiang J, Li Z, Jiang D, Shi X, et al.
Nat Commun
. 2022 Aug;
13(1):4495.
PMID: 35918337
While hypoxia promotes carcinogenesis, tumour aggressiveness, metastasis, and resistance to oncological treatments, the impacts of hyperoxia on tumours are rarely explored because providing a long-lasting oxygen supply in vivo is...
5.
Zhang L, Yang H, Qian C, Zhou J, Zhu Q, Jiang Y, et al.
Hematology
. 2022 Apr;
27(1):404-411.
PMID: 35413224
Objectives: The aim of this retrospective study was to evaluate the safety and efficacy of SEAM regimen followed by auto-SCT in lymphoma. Patients And Methods: We retrospectively reviewed the records...
6.
Xu J, Ma Q, Zhang Y, Fei Z, Sun Y, Fan Q, et al.
Nat Commun
. 2022 Jan;
13(1):110.
PMID: 35013252
Microbe-based cancer immunotherapy has recently emerged as a hot topic for cancer treatment. However, serious limitations remain including infection associated side-effect and unsatisfactory outcomes in clinic trials. Here, we fabricate...
7.
Gu B, Chu J, Wu D
Front Med
. 2020 Dec;
14(6):701-710.
PMID: 33263835
Chimeric antigen receptor T cell (CAR T) therapies have achieved unprecedented efficacy in B-cell tumors, prompting scientists and doctors to exploit this strategy to treat other tumor types. Acute myeloid...
8.
Jiang D, Tian X, Bian X, Zhu T, Qin H, Zhang R, et al.
Leukemia
. 2019 Oct;
34(3):821-830.
PMID: 31624374
CD19-redirected CAR-T immunotherapy has emerged as a promising strategy for treatment of B cell lymphoma, however, many patients often relapsed due to antigen loss. Therefore, it is urgently needed to...
9.
Wang F, Meng M, Mo B, Yang Y, Ji Y, Huang P, et al.
Nat Commun
. 2018 Nov;
9(1):4874.
PMID: 30451838
The metabolic checkpoint kinase mechanistic/mammalian target of rapamycin (mTOR) regulates natural killer (NK) cell development and function, but the exact underlying mechanisms remain unclear. Here, we show, via conditional deletion...
10.
Wang Y, Chu J, Yi P, Dong W, Saultz J, Wang Y, et al.
J Clin Invest
. 2018 Sep;
128(11):5123-5136.
PMID: 30183689
SMAD4 is the only common SMAD in TGF-β signaling that usually impedes immune cell activation in the tumor microenvironment. However, we demonstrated here that selective deletion of Smad4 in NK...